

Clinical Guidelines and Related Provider Requirements: Pharmacologic Treatment of ADHD in Children and Adolescents

Community Behavioral Health (CBH) has adopted Clinical Practice Guidelines (CPGs) to outline best practices for the treatment of specific disorders or certain populations. These guidelines will be used by CBH to assess the quality of care provided to CBH members. As such, providers are advised to review and, where appropriate, implement these best practices in their care. CPGs apply to all clinical settings where care is delivered to members. CPGs should be used in conjunction with any level-of-care-specific performance standards, as well as all other required CBH, NIAC, state, and federal regulations and standards.

CBH has updated the existing guidelines for the treatment of adults with major depressive disorder. The most recent versions of all CPGs can now be found on the [Clinical Practice Guidelines webpage](#).

Significant changes to the ADHD Clinical Practice Guidelines include:

- New section (3.6) addressing safety and diversion
- Updates to FDA-approved ADHD medications (section 5.3)

Adherence to the CPGs will be assessed through CBH monitoring and oversight, including Quality, Clinical, and Compliance Department protocols. Additionally, components may be reviewed as part of the Network Improvement and Accountability Collaborative (NIAC) initial and recredentialing reviews. To assess quality of care and align with state and regulatory requirements, CBH will also be utilizing several specific metrics for the CPG, which are detailed in the table below.

<i>Clinical Guidelines</i>	<i>Quality Metrics</i>
<p><u>Clinical Practice Guidelines for the Pharmacologic Treatment of ADHD in Children and Adolescents</u></p>	<ul style="list-style-type: none"> ➤ HEDIS ADD: Appropriate medication follow-up appointment for children and adolescents prescribed medications for ADHD in initiation and continuation phase ➤ Appropriate use of medication for children and adolescents diagnosed with ADHD (percentage of members with ADHD prescribed FDA-approved medications, other medications, and no medication)

These requirements take effect on March 12, 2024. Please direct questions to Stephanie Byers at stephanie.byers@phila.gov.